METHODS: This retrospective cohort study, conducted at an academic medical centre, included 141 adult patients with AUD who received XR-NTX between December 2020 and June 2021. Primary and secondary outcomes were assessed 90 days before and after XR-NTX administration to identify number of alcohol-related hospitalisations, emergency department (ED) visits and average length of hospital stay. Subgroup analyses assessed outcomes in high hospital utilisers and marginally housed or unhoused populations.
RESULTS: There was a significant decrease in ED visits and length of hospital stay post XR-NTX and no significant difference in the number of rehospitalisations. Subgroup analysis showed significant reduction in hospital readmissions and ED visits among high hospital utilisers. Our sample was a predominantly middle-aged, male and white patient population.
CONCLUSIONS: In-hospital initiation of XR-NTX for AUD was associated with a significant decrease in ED visits and length of hospital stay. While no significant impact on the number of hospitalisations was observed overall, there was a substantial reduction in hospital readmissions and ED visits among high utilisers. Our findings suggest the potential benefits of in-hospital XR-NTX, emphasising the need for further research to establish causal relationships, assess cost-effectiveness and explore effectiveness across diverse patient populations. Effective in-hospital interventions, such as XR-NTX, hold promise for improving patient outcomes and reducing the healthcare burden associated with AUD.
方法:这项回顾性队列研究,在学术医疗中心进行,纳入了141名在2020年12月至2021年6月期间接受XR-NTX的AUD成年患者。在XR-NTX给药之前和之后90天评估主要和次要结局,以确定与酒精相关的住院次数。急诊科(ED)就诊次数和平均住院时间。亚组分析评估了高医院使用率和边缘住房或无住房人群的结果。
结果:XR-NTX后,ED就诊次数和住院时间显着减少,而再住院次数没有显着差异。亚组分析显示,高医院使用率患者的再入院率和ED就诊率显着减少。我们的样本主要是中年人,男性和白人患者。
结论:住院开始XR-NTX治疗AUD与ED就诊次数和住院时间显著减少相关。虽然总体上对住院人数没有显著影响,高使用率患者的再入院率和急诊就诊率大幅下降.我们的研究结果表明,院内XR-NTX的潜在益处,强调需要进一步研究以建立因果关系,评估成本效益并探索不同患者人群的有效性。有效的住院干预措施,例如XR-NTX,有望改善患者预后并减轻与AUD相关的医疗负担。